Fiona E Smyth
Overview
Explore the profile of Fiona E Smyth including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
549
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Perani A, Gloria B, Wang D, Buffier A, Berteau O, Esteban G, et al.
BMC Proc
. 2012 Mar;
5 Suppl 8:P16.
PMID: 22373522
No abstract available.
2.
Perani A, Gloria B, Wang D, Murphy R, Singh H, Smyth F, et al.
BMC Proc
. 2012 Mar;
5 Suppl 8:P17.
PMID: 22373023
No abstract available.
3.
Johns T, McKay M, Cvrljevic A, Gan H, Taylor C, Xu H, et al.
Int J Radiat Oncol Biol Phys
. 2010 Jul;
78(2):572-8.
PMID: 20638193
Purpose: Mutations of the epidermal growth factor receptor (EGFR) are common in glioma. The most frequent mutation, de2-7 EGFR/EGFRvIII, occurs in approximately 40% of high-grade gliomas and confers resistance to...
4.
Lee F, OKeefe G, Gan H, Mountain A, Jones G, Saunder T, et al.
J Nucl Med
. 2010 May;
51(6):967-72.
PMID: 20484439
Unlabelled: Overexpression, activation, and mutations of the epidermal growth factor receptor (EGFR) are commonly found in solid tumors. The aim of this study was to develop a PET-based method for...
5.
Herbertson R, Tebbutt N, Lee F, Macfarlane D, Chappell B, Micallef N, et al.
Clin Cancer Res
. 2009 Oct;
15(21):6709-15.
PMID: 19825951
Purpose: This phase I study explored the biodistribution and pharmacokinetics of the immunoconjugate CMD-193 [a humanized anti-Lewis Y (Le(y)) antibody conjugated with calicheamicin in patients with advanced cancers expressing the...
6.
Kelly M, Lee S, Lee F, Smyth F, Davis I, Brechbiel M, et al.
Prostate
. 2008 Oct;
69(1):92-104.
PMID: 18942092
Background: This study investigated the biodistribution and therapeutic efficacy of Lutetium-177 (177Lu) radiolabeled anti-Lewis Y monoclonal antibody hu3S193 radioimmunotherapy (RIT) in mice bearing prostate cancer xenografts. The ability of epidermal...
7.
Kelly M, Lee F, Tahtis K, Power B, Smyth F, Brechbiel M, et al.
Cancer Biother Radiopharm
. 2008 Sep;
23(4):411-23.
PMID: 18771345
The use of single-chain variable fragment (scFv) constructs has been investigated in cancer radioimmunotherapy (RIT) and radioimmunodetection, as these molecules permit rapid tumor penetration and clearance from the serum relative...
8.
Kelly M, Lee F, Tahtis K, Smyth F, Brechbiel M, Scott A
Clin Cancer Res
. 2007 Sep;
13(18 Pt 2):5604s-5612s.
PMID: 17875796
Purpose: Previous experience in solid tumor radioimmunotherapy studies has indicated that greatest therapeutic efficacy is achieved in the treatment of small-volume disease. alpha-Particle-emitting radioisotopes possess several physical characteristics ideally suited...
9.
Davis I, Liu Z, Saunders W, Lee F, Spirkoska V, Hopkins W, et al.
Cancer Immun
. 2007 Aug;
7:14.
PMID: 17705350
The chimeric monoclonal antibody cG250 recognizes the CAIX/MN antigen. cG250 induces antibody-dependent cellular cytotoxicity (ADCC) responses in vitro that can be enhanced by IL-2. We studied the effects of adding...
10.
Scott A, Tebbutt N, Lee F, Cavicchiolo T, Liu Z, Gill S, et al.
Clin Cancer Res
. 2007 Jun;
13(11):3286-92.
PMID: 17545534
Purpose: We report a first-in-man trial of a humanized antibody (hu3S193) against the Le(y) antigen. Experimental Design: Patients with advanced Le(y)-positive cancers received four infusions of hu3S193 at weekly intervals,...